BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

Harbour BioMed’s HBM9378 Shows Sustained Asthma Control with Twice-Yearly Dosing Potential

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. ...

September 10, 2026 | News

The Arbitrage Triangle

METHOD IN BRIEF Flow estimates come from published government statistics and press reporting of official material; no authority in the region publishes in...

September 09, 2026 | Analysis

Clover Biopharmaceuticals Reports Positive Phase II Results for RSV-hMPV-PIV3 Combination Vaccines

-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differe...

September 08, 2026 | News

Where the Longevity Money Actually Goes

METHOD IN BRIEF Window: 1 January to 31 August 2026 for round-level claims, with full-year 2024 and 2025 figures for context. Attribution follows scientif...

September 07, 2026 | Analysis

Nobody Is the Payer

A gerotherapeutic that delays five diseases by three years each would produce savings across five budget lines over thirty years, and a cost that lands in ...

September 04, 2026 | Analysis

Akeso’s Ivonescimab Shows Significant Overall Survival Benefit Over Pembrolizumab in Phase III NSCLC Trial

Akeso, Inc. announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Dat...

September 04, 2026 | News

The Biological Age Business

On coming 4th September at six in the evening Singapore time, a public consultation will close. It opened on 7 August, it is still open as this is publishe...

August 27, 2026 | Analysis

The Sarcopenia Definition Race: The Endpoint Is the Asset

In a category with no approvable indication anywhere in the world, whoever writes the endpoint definition controls who is eligible for a trial, what counts...

August 12, 2026 | Analysis

Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializin...

August 12, 2026 | News

Reading the Register: What Japan's Provision Plans Actually Say

A register, not an approval list Start with the thing that is most often got wrong, including by people who should know better. The Act on the Safety of ...

August 10, 2026 | Analysis

10 Bioprocessing Bottlenecks and How APAC Plants Are Clearing Them

How this list was built Ten bottlenecks were identified from facility interviews, technical sessions at regional bioprocessing conferences and pub...

August 05, 2026 | Analysis

9 AI Drug Discovery Platforms Built in Asia-Pacific, and What They Have Actually Shipped

For most of the past decade, the only honest answer to the question of whether AI drug discovery works in Asia-Pacific was that nobody could yet know. The ...

August 04, 2026 | Analysis

7 Manufacturing Technologies Moving From Pilot to Plant in APAC

HOW THE SEVEN WERE CHOSEN Inclusion required evidence of at least two commercial-scale installations in the region, with sites named wherever publ...

August 03, 2026 | Analysis

8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026

Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...

July 29, 2026 | Analysis

Stay Connected